

# Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/AA22CA92D6FAEN.html>

Date: August 2022

Pages: 243

Price: US\$ 2,500.00 (Single User License)

ID: AA22CA92D6FAEN

## Abstracts

Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Drugs In Development, 2022, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development

history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 4, 9, 1, 2, 49, 14 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 19 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).

The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Atherosclerosis - Overview

Atherosclerosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Atherosclerosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Atherosclerosis - Companies Involved in Therapeutics Development

Atherosclerosis - Drug Profiles

Atherosclerosis - Dormant Projects

Atherosclerosis - Discontinued Products

Atherosclerosis - Product Development Milestones

Featured News & Press Releases

May 31, 2022: Amgen announces positive topline phase 2 data for investigational Olpasiran in adults with elevated lipoprotein(a)

May 22, 2022: Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease

Apr 05, 2022: NewAmsterdam Pharma doses first patient in phase 2 trial of Obicetrapib in combination with Ezetimibe as an adjunct to high-intensity statin therapy

Mar 01, 2022: NewAmsterdam Pharma doses first patient in PREVAIL, the cardiovascular outcomes trial of obicetrapib in adults with atherosclerotic cardiovascular disease (ASCVD)

Feb 14, 2022: New review article in ESC's Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) inhibition's role in reducing cardiovascular disease risk

Feb 08, 2022: Leqvio therapy to lower cholesterol approved by FDA, IVX Health now accepting new Leqvio patients

Jan 04, 2022: NewAmsterdam Pharma doses first patient in phase 3 BROADWAY trial of obicetrapib in adults with heterozygous familial hypercholesterolemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD)

Dec 22, 2021: FDA approves Novartis Leqvio (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Nov 08, 2021: Leqvio (inclisiran) reduced LDL-C in people who are overweight or obese

Sep 23, 2021: Verve Therapeutics reports new preclinical data with VERVE-101 demonstrating robust, durable and precise editing of the PCSK9 gene for the treatment of Cardiovascular Disease

Sep 01, 2021: World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio(inclisiran)

Aug 30, 2021: Novartis Leqvio (inclisiran) analyses show effective and sustained LDL-C reduction in two sub-populations of patients with ASCVD

Jun 15, 2021: Preclinical data from ImmunoPrecise's drug pipeline to be presented during the BIO International partnering event

Jun 03, 2021: Afimmune announces positive data with Epeleuton from preclinical atherosclerosis studies

May 18, 2021: Novo Nordisk's ziltivekimab shows promise in Phase II CKD trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Atherosclerosis, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Number of Products under Development by Universities/Institutes, 2022 (Contd..1)  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Products under Development by Universities/Institutes, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Target, 2022 (Contd..1)  
Number of Products by Stage and Target, 2022 (Contd..2)  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)  
Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Atherosclerosis - Dormant Projects, 2022  
Atherosclerosis - Discontinued Products, 2022  
Atherosclerosis - Discontinued Products, 2022 (Contd..1)  
Atherosclerosis - Discontinued Products, 2022 (Contd..2)

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Atherosclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/AA22CA92D6FAEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA22CA92D6FAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

